e-learning
resources
Madrid 2019
Monday, 30.09.2019
Real-world experience of monoclonal antibodies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria
D. Hristova (Sofia, Bulgaria), T. Kralimarkova (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria)
Source:
International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Session:
Real-world experience of monoclonal antibodies in asthma
Session type:
Thematic Poster
Number:
2531
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Hristova (Sofia, Bulgaria), T. Kralimarkova (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria). Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria. 2531
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018
Year: 2018
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Year: 2021
Severe asthma outcomes over two years of therapy with mepolizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece.
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept